Pompilio, Giuseppe, Alessandro Morabito, Diego L. Cortinovis, and Davide Integlia. “Budget Impact Analysis of Afatinib for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients With Uncommon EGFR Mutations”. Global and Regional Health Technology Assessment 9, no. 1 (January 31, 2022): 22–29. Accessed November 23, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/2351.